All News

22 February 2012

UCB announces start of C-EARLY™ study for Cimzia (certolizumab pegol) in rheumatoid arthritisAntibodies

20 February 2012

Takeda Announces Primary Endpoints Met for Pivotal Phase 3 Trial of Vedolizumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Have Failed at Least One Conventional TherapyAntibodies

20 February 2012

Positive One Year results From Phase 3 Study in Central Retinal Vein Occlusion of VEGF Trap-EyeAntibodies

9 February 2012

In-vivo proof of concept achieved by targeting of IL1RAP on human tumorAntibodies

8 February 2012

Amgen to Discuss Application for New Use of XGEVA® (denosumab) at FDA Oncologic Drugs Advisory Committee MeetingAntibodies

8 February 2012

ARGEN-X ADVANCES A THIRD THERAPEUTIC ANTIBODY PROGRAM INTO PRECLINICAL DEVELOPMENTAntibodies

7 February 2012

FDA Grants Genentech’s Pertuzumab Priority Review for Previously Untreated HER2-Positive Metastatic Breast CancerAntibodies

2 February 2012

Compugen Cancer Target Results Demonstrate Significant Potential for Cancer ImmunotherapyAntibodies

30 January 2012

VGX-100 Identified as Potential New Therapy for Improving Corneal Graft SurvivalAntibodies

30 January 2012

biOasis Advances its Herceptin(R) BT2111 ProgramAntibodies

29 January 2012

Lpath Temporarily Suspends Dosing of iSONEP in Clinical Trials Due to cGMP Compliance Issues at Contract Fill/Finish SourceAntibodies

29 January 2012

Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS in Front-line Mature T-Cell LymphomasAntibodies

29 January 2012

Seattle Genetics Announces Data from ADCETRIS in Cutaneous T-Cell Lymphoma and Peripheral T-Cell LymphomaAntibodies

26 January 2012

ASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progressive Multiple SclerosisAntibodies

25 January 2012

Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALINAntibodies

24 January 2012

Baxter to Initiate Second Phase III Trial Studying GAMMAGARD LIQUID (IGIV) for the Treatment of Alzheimer’s DiseaseAntibodies

23 January 2012

ZEVALIN Plus High Dose Chemotherapy (Z-BEAM) Highly Effective in Aggressive Lymphoma; Randomized Study Published in “CANCER”, the Journal of the American Cancer SocietyAntibodies

21 January 2012

Remicade® (Infliximab) Receives Positive Opinion From CHMP In Europe for Treatment of Ulcerative Colitis in Pediatric PatientsAntibodies

21 January 2012

Immunomedics Reports Final Results From Phase Ib/II Study of Yttrium-90-Labeled Clivatuzumab Tetraxetan and Gemcitabine in Advanced Pancreatic CancerAntibodies

21 January 2012

FDA Updates TYSABRI® (natalizumab) Label to Include Anti-JC Virus Antibody Status as a PML Risk FactorAntibodies

18 January 2012

InflaRx Announces Successful Conduct of Its Clinical Phase I Trial with IFX-1, a New Monoclonal Antibody Inhibiting Complement Driven InflammationAntibodies

13 January 2012

Seattle Genetics Announces Updates to ADCETRIS™ Prescribing InformationAntibodies

13 January 2012

Genentech Announces First Milestone Payment to Device-Maker ForSight VISION4, Inc. in Development of Sustained Delivery LucentisAntibodies

12 January 2012

Three Adimab Antibodies Enter Human Clinical TrialsAntibodies

9 January 2012

Biocon Announces Positive Efficacy Data with its Novel Monoclonal Antibody Itolizumab in a Pivotal Psoriasis StudyAntibodies

9 January 2012

Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer PatientsAntibodies

9 January 2012

Thallion and LFB Complete Patient Enrollment of Phase II SHIGATEC TrialAntibodies

9 January 2012

Baxter Submits Application for FDA Approval of GAMMAGARD LIQUID to Treat Multifocal Motor Neuropathy, a Degenerative Neurological DisorderAntibodies

2 January 2012

Emergent Announces Plans for TRU-016 Program Following Termination of Collaboration with AbbottAntibodies

30 December 2011

Roche medicine Avastin receives EU approval for the treatment of women with newly diagnosed, advanced ovarian cancerAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

5T4-Targeted Immunotherapy Candidates Pipeline Review

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

CD38-Targeted Antibody & Cell Therapy Pipeline Review

Report Package: Bispecific Antibodies

Adalimumab (Humira) Biosimilars Pipeline Review

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective